Clinical trials: Radiotracer
Healthy Subjects
A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1
The objective of this trial is to assess the post-infusion viability of INTERCEPT RBCs by measuring the 24-hour post-infusion recovery and lifespan of autologous RBCs prepared with the INTERCEPT Blood System for RBC with AS-1…
- Trial name
- NCT07015437
- Testing
- INTERCEPT Blood System for RBCs, Infusion of autologous radiolabeled RBCs
- Where
- 2 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Cerus Corporation
Pulmonary Disease, Chronic Obstructive
To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]SB-681323 in Healthy Adult Males
SB-681323 is a p38 MAP kinase inhibitor and is currently under development by GlaxoSmithKline. This will be an open label study conducted at one site.
- Trial name
- NCT00564746
- Testing
- A single 10 milligram (50 microcurie) oral dose of [14C]SB-681323
- Where
- United Kingdom
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Sleep Initiation and Maintenance Disorders
Radiolabel Study In Healthy Volunteers For Insomnia-Targeting Drug
The purpose of this study is to define the absorption, breakdown and excretion of a single dose of radiolabelled SB-649868 and its breakdown products by measuring their concentration in blood, urine and faeces over a 7-10 day…
- Trial name
- NCT00520663
- Testing
- 14C-SB649868
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Parkinson Disease
A Positron Emission Tomography (PET) Study to Examine the Brain Binding Properties of a Novel Radioactive Compound [11C]-PXT012253 in Healthy Subjects
This study evaluates the usefulness of a PET radioligand to estimate the binding on the mGlu4 receptor in the brain. mGlu4 has been proposed as a therapeutic target in Parkinson's disease.
- Trial name
- NCT03826134
- Testing
- [11C]PXT012253
- Where
- Sweden
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Ischemic Heart Disease (IHD)
XTR003 PET Radiotracer for the Detection of Viable Myocardium
The study was designed to explore the clinical feasibility of XTR003, a PET myocardial fatty-acid tracer, for the detection of viable myocardium in patients with ischemic heart disease (IHD).
- Trial name
- NCT05885854
- Testing
- XTR003
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Sinotau Pharmaceutical Group
Carcinoma, Renal Cell
Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034
To study the absorption, distribution, metabolism and excretion of GW786034, and the absorption of a single IV dose of GW786034
- Trial name
- NCT00478725
- Testing
- GW786034, oral, GW786034, IV, GW786034, radiolabeled oral
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Solid Tumors, Brain Metastases
18F ML-10 for Early Detection of Response of Brain Metastases to WBRT
The purpose of this study is to evaluate the potential of [18F]-ML-10 to serve as a non-invasive imaging tool for the early detection of apoptosis in brain metastases in response to radiation therapy.
- Trial name
- NCT00791063
- Testing
- 18F ML-10
- Volunteers
- 10 people
- Sponsor
- Aposense Ltd.
Pulmonary Disease, Chronic Obstructive
Absorption & Elimination of Radiolabelled GSK2269557
GSK2269557 is being developed as an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease (COPD) and other inflammatory lung diseases such as asthma.
- Trial name
- NCT03315559
- Testing
- [14C]-GSK2269557 IV infusion, GSK2269557 via DPI, [14C]-GSK2269557 oral solution
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Neuroinflammation
Test Re-Test Reliability of [11C]PF-06809247 as a Novel PET Tacer
This is a study measuring the binding kinetics and test-retest characteristics of a subpharmacological dose of [11C]PF-06809247 Monoacylglycerol lipase (MAGL) Positron Emission Tomography (PET) tracer in healthy adult subjects.
- Trial name
- NCT03100136
- Testing
- [11C]PF-06809247
- Where
- 3 sites in United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study To Investigate The Absorption, Distribution, Metabolism, And Excretion Of [14c]PF-06463922 In Healthy Male Volunteers
The study aims to understand, using radiolabelled PF-06463922, how this compound is modified by the body once it is absorbed. The study also aims to understand how much of the compound is broken down and how much leaves the body…
- Trial name
- NCT02564562
- Testing
- [14C] PF-06463922
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
HCV
Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Adult Male Subjects
This is a phase 1 study to assess the routes of elimination of a single oral dose of [14C] PF-00868554 and to characterize the metabolic profile following single dose administration.
- Trial name
- NCT00823745
- Testing
- [14C]-PF-00868554
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Phase I Study to Determine the Absorption, Distribution, Metabolism and Excretion of Esreboxetine
The purpose of the study is to learn more about how esreboxetine is handled by the body i.e. the absorption, metabolism and excretion of esreboxetine.
- Trial name
- ADME (NCT00800956)
- Testing
- [14C]-esreboxetine
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Adult
Evaluation of the Pharmacokinetics, Biodistribution and Radiation Dosimetry of [18F]MODAG-009 Positron Emission Tomography (PET) Radiotracers in Adult Healthy Volunteers
This is an open-label, single-center, phase 1 study to further characterize [18F]MODAG-009 in Healthy Volunteers (HV). Approximately 6 participants will be enrolled in this study.
- Trial name
- NCT07617688
- Testing
- [¹⁸F]MODAG-009 PET Imaging
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- MODAG GmbH
Healthy Volunteers
A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers
This study will estimate how fast two antiepileptic drugs (Levetiracetam and Brivaracetam) enter the human brain. Brain imaging will be used to measure how quickly the radioactive probe [11C]UCB-J exits the brain when…
- Trial name
- NCT02602860
- Testing
- [11C]UCB-J, Brivaracetam, Levetiracetam
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- UCB Pharma
Healthy Subjects
A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.
The objective of this study is to assess the post-infusion recovery and survival of platelets in 100% Plasma treated with INTERCEPT Blood System for Platelets with LED Illuminator and stored for 5 days after apheresis collection.
- Trial name
- NCT06697223
- Testing
- INTERCEPT Blood System for Platelets with LED Illuminator
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cerus Corporation
Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms
An Efficacy and Safety Study to Assess [18F]-ML-10 in Detecting Response of Tumors to Chemotherapy and Radiation
The purpose of this study is to determine whether [18F]-ML-10 used in conjunction with PET imaging is effective as an imaging tool for the early detection of response of oncological tumors in the lungs,head and neck to…
- Trial name
- NCT01260480
- Testing
- [18F]-ML-10 in conjunction with PET imaging
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Aposense Ltd.
Hyperhidrosis
Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects
The purpose of this study is to characterize the pharmacokinetics (PK), safety and tolerability of topically applied umeclidinium following single dose topical administration.
- Trial name
- NCT01934153
- Testing
- [14C]Umeclidinium 18.5 mg
- Where
- Netherlands
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Study To Understand How Radiolabelled PF-04449913 Is Taken Up By The Body, Broken Down And Then Removed From The Body
The study aims to understand, using radiolabelled PF-04449913, how this compound is modified by the body once it is absorbed. The study also aims to understand how much of the compound is broken down and how much leaves the body…
- Trial name
- NCT02110342
- Testing
- [14C] PF-04449913
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Coronary Artery Disease (CAD), Myocardial Ischemia
A Study of XTR004 Radiotracer in Healthy Volunteers
XTR004 is a 18F-labeled myocardial perfusion positron emission tomography tracer use to measure myocardial perfusion and myocardial blood flow.
- Trial name
- NCT05195879
- Testing
- XTR004
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Sinotau Pharmaceutical Group
Type 2 Diabetes Mellitus (T2DM)
A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)
This is single dose study of radiolabeled [14C]-ertugliflozin (PF04971729, MK-8835) in healthy male volunteers to study the absorption, distribution, metabolism and elimination of ertugliflozin.
- Trial name
- NCT01127308
- Testing
- Ertugliflozin
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC